Plaintiff

Adapt Pharma Operations Limited

3 cases as plaintiff.

Cases
3
Active
0
3 closed
Filed
2016–2018
Top venue
D. New Jersey
3 cases

Company profile

Adapt Pharma Operations Limited is an Irish-registered pharmaceutical entity and part of the Adapt Pharma group (alongside Adapt Pharma Limited and Adapt Pharma Inc.). The group was founded in 2014 in Dublin by Séamus Mulligan, David Brabazon and Eunan Maguire, with Irish headquarters at Fitzwilliam Square, Dublin 2, and US headquarters in Radnor, Pennsylvania (Irish Times; Pharmaceutical Business Review). Adapt was privately held until Emergent BioSolutions agreed in August 2018 to acquire it for up to $735 million ($635 million upfront plus $100 million in sales milestones), closing in October 2018 (Emergent press release; Baltimore Sun). It is therefore now a subsidiary of publicly traded Emergent BioSolutions (NYSE: EBS) and was subsequently renamed Emergent Operations Ireland Limited (Gazzetta Ufficiale, 2021).

Products / operations. Adapt's business was commercializing NARCAN (naloxone hydrochloride) Nasal Spray 4 mg, the first FDA-approved needle-free naloxone nasal spray for emergency opioid-overdose reversal (approved November 2015; launched early 2016; Health Canada approval October 2016). The product was licensed from Opiant Pharmaceuticals (formerly Lightlake Therapeutics) under a December 2014 agreement. Adapt also had a small pipeline of overdose/addiction treatments. It was a lean commercial organization: Irish filings for Adapt Pharma Operations Ltd reported roughly $134.9 million revenue and 17 employees for 2018; the Emergent deal brought about 50 employees across the US, Canada and Ireland (Irish Times; Emergent/PharmTech).

Litigation posture. Adapt is an operating company and appears in the database exclusively as a plaintiff (3 cases, 0 as defendant), all Hatch-Waxman ANDA actions filed in the U.S. District Court for the District of New Jersey — a common venue for branded pharma suits against generics, not a plaintiff-friendly NPE venue.

Notable cases. The tracked suits are Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc. (2016 and 2018) and Adapt Pharma Operations Ltd. v. Perrigo UK FINCO Ltd. Partnership (2018), each targeting a generic naloxone nasal spray. The Teva case reached a 2020 bench trial in which the asserted NARCAN patents were held obvious; the Federal Circuit affirmed in Adapt Pharma Operations v. Teva (25 F.4th 1354, Feb. 10, 2022), with Judge Newman dissenting.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

stayed
Docket:
2:18-cv-05752
Filed:
2018-04-09
Terminated:
2022-07-27

Hatch-Waxman/ANDA suit filed by Adapt Pharma and Opiant against Teva, triggered by Teva's Paragraph IV notice regarding ANDA No. 211561 for generic NARCAN 2 mg/spray. The case asserted U.S. 9,480,644 and U.S. 9,707,226. On July 28, 2020, the court stayed the case pending resolution of the related 4 mg Naloxone Case appeal; the final docket entry is dated July 27, 2022.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

judgment (invalidity); affirmed on appeal
Docket:
2:16-cv-07721 (JLL)(JAD); 2:17-cv-00864; 2:17-cv-02877; 2:17-cv-05100; 2:18-cv-09880
Filed:
2016-11-26
Terminated:
2020-06-26

Adapt and Opiant sued Teva in D.N.J. asserting NARCAN naloxone nasal spray patents. The district court found the asserted patents invalid for obviousness on June 5, 2020, with judgment entered June 26, 2020; the Federal Circuit affirmed on Feb. 10, 2022. The '570 patent was not asserted but was cited as prior art (Wyse). Consolidated/related docket numbers included 2:17-cv-00864, 2:17-cv-02877, 2:17-cv-05100, 2:18-cv-09880; related Perrigo action 2:18-cv-15287.

Adapt Pharma Operations Limited et al. v. Perrigo UK FINCO Limited Partnership

related action
Docket:
2:18-cv-15287

Related Perrigo action in the D.N.J. NARCAN litigation; Perrigo UK FINCO Limited Partnership named as defendant. The '570 patent was not asserted; it was prior art (Wyse) in the related litigation.